WO2002013873A3 - Compositions de composes conjugues a p97 et leurs methodes d'utilisation - Google Patents

Compositions de composes conjugues a p97 et leurs methodes d'utilisation Download PDF

Info

Publication number
WO2002013873A3
WO2002013873A3 PCT/US2001/025787 US0125787W WO0213873A3 WO 2002013873 A3 WO2002013873 A3 WO 2002013873A3 US 0125787 W US0125787 W US 0125787W WO 0213873 A3 WO0213873 A3 WO 0213873A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
organs
methods
active agent
agent conjugates
Prior art date
Application number
PCT/US2001/025787
Other languages
English (en)
Other versions
WO2002013873A2 (fr
WO2002013873A9 (fr
Inventor
Reinhard Gabathuler
Timothy Vitalis
Gerrassimos Kolaitis
Robert Charles Brooks
Dalara M Karkan
Gavin D Arthur
Pierre Jean Paul St
Original Assignee
Synapse Tech Inc
Reinhard Gabathuler
Timothy Vitalis
Gerrassimos Kolaitis
Robert Charles Brooks
Dalara M Karkan
Gavin D Arthur
Pierre Jean Paul St
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synapse Tech Inc, Reinhard Gabathuler, Timothy Vitalis, Gerrassimos Kolaitis, Robert Charles Brooks, Dalara M Karkan, Gavin D Arthur, Pierre Jean Paul St filed Critical Synapse Tech Inc
Priority to AU2001285020A priority Critical patent/AU2001285020A1/en
Publication of WO2002013873A2 publication Critical patent/WO2002013873A2/fr
Publication of WO2002013873A9 publication Critical patent/WO2002013873A9/fr
Publication of WO2002013873A3 publication Critical patent/WO2002013873A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des compositions d'administration de médicaments offrant une administration améliorée d'agents thérapeutiques dans des organes sélectionnés, et notamment dans des organes autres que le système nerveux central (SNC). Les compositions de l'invention sont utiles pour le traitement de maladies associées à ces organes. Par ailleurs, ces compositions permettent de réduire la toxicité systémique desdits composés. Dans certains modes de réalisation, ces compositions pharmaceutiques renferment un composé conjugué à p97 ou à un fragment de ce dernier, ainsi qu'un excipient pharmaceutiquement acceptable.
PCT/US2001/025787 2000-08-17 2001-08-17 Compositions de composes conjugues a p97 et leurs methodes d'utilisation WO2002013873A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001285020A AU2001285020A1 (en) 2000-08-17 2001-08-17 P97-active agent conjugates and their methods of use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22624200P 2000-08-17 2000-08-17
US22625400P 2000-08-17 2000-08-17
US60/226,242 2000-08-17
US60/226,254 2000-08-17

Publications (3)

Publication Number Publication Date
WO2002013873A2 WO2002013873A2 (fr) 2002-02-21
WO2002013873A9 WO2002013873A9 (fr) 2003-01-30
WO2002013873A3 true WO2002013873A3 (fr) 2003-05-01

Family

ID=26920335

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/025787 WO2002013873A2 (fr) 2000-08-17 2001-08-17 Compositions de composes conjugues a p97 et leurs methodes d'utilisation

Country Status (2)

Country Link
AU (1) AU2001285020A1 (fr)
WO (1) WO2002013873A2 (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7297511B2 (en) 2001-10-10 2007-11-20 Neose Technologies, Inc. Interferon alpha: remodeling and glycoconjugation of interferon alpha
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
EP2305311A3 (fr) 2001-10-10 2011-07-20 BioGeneriX AG Glycoconjugation des peptides
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7399613B2 (en) 2001-10-10 2008-07-15 Neose Technologies, Inc. Sialic acid nucleotide sugars
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7179617B2 (en) 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US7439043B2 (en) 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
ES2516041T3 (es) 2001-10-10 2014-10-30 Ratiopharm Gmbh Remodelación y glicoconjugación de la hormona del crecimiento humano (hGH)
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7226903B2 (en) 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
US7473680B2 (en) 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
JP2006506317A (ja) 2002-01-11 2006-02-23 バイオマリン ファーマシューティカル インコーポレイテッド 治療用リソソーム酵素の送達のための酵素送達系としてのｐ９７の使用
KR20060003862A (ko) 2003-03-14 2006-01-11 네오스 테크놀로지스, 인크. 수용성분기폴리머 및 그 접합체
MXPA05010773A (es) 2003-04-09 2005-12-12 Neose Technologies Inc Metodos de glicopegilacion y proteinas/peptidos producidos por los metodos.
EP1613261A4 (fr) 2003-04-09 2011-01-26 Novo Nordisk As Formation intracellulaire de conjugues de peptides
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
WO2005012484A2 (fr) 2003-07-25 2005-02-10 Neose Technologies, Inc. Conjugues anticorps-toxines
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
AU2004293103C1 (en) 2003-11-24 2010-12-02 Ratiopharm Gmbh Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
BRPI0506741A (pt) 2004-01-08 2007-05-15 Neose Technologies Inc glicosilação de peptìdeos ligados a o
BRPI0510295A (pt) 2004-05-04 2007-11-06 Novo Nordisk Healthcare Ag preparação de uma glicoproteìna, e, método para produzir a mesma
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
US8268967B2 (en) 2004-09-10 2012-09-18 Novo Nordisk A/S Glycopegylated interferon α
JP5948627B2 (ja) 2004-10-29 2016-07-20 レイショファーム ゲーエムベーハー 線維芽細胞成長因子（ｆｇｆ）のリモデリングと糖質ペグ化
EP1858543B1 (fr) 2005-01-10 2013-11-27 BioGeneriX AG Facteur de stimulation de colonie de granulocytes glycopegylé
US20070154992A1 (en) 2005-04-08 2007-07-05 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
JP5216580B2 (ja) 2005-05-25 2013-06-19 ノヴォ ノルディスク アー／エス グリコペグ化第ｉｘ因子
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
CN101516388B (zh) 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
EP2054521A4 (fr) 2006-10-03 2012-12-19 Novo Nordisk As Méthodes de purification de conjugués de polypeptides
RS52845B (en) 2007-04-03 2013-12-31 Biogenerix Ag TREATMENT PROCEDURES USING GLYCOPEGILATED G-CSF
US9493499B2 (en) 2007-06-12 2016-11-15 Novo Nordisk A/S Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography
EP2257311B1 (fr) 2008-02-27 2014-04-16 Novo Nordisk A/S Molécules de facteur viii conjuguées
US8828925B2 (en) * 2008-10-15 2014-09-09 Angiochem Inc. Etoposide and doxorubicin conjugates for drug delivery
MX2011004017A (es) 2008-10-15 2011-06-24 Angiochem Inc Conjugados de agonistas glp-1 y usos de los mismos.
EP2216341A1 (fr) 2009-02-10 2010-08-11 Novozymes Biopharma UK Limited Variantes de la transferrine et conjugués
PT2717917T (pt) 2011-07-05 2016-07-27 Bioasis Technologies Inc Conjugados de anticorpos p97
ES2654111T3 (es) * 2011-08-05 2018-02-12 Bioasis Technologies Inc. Fragmentos p97 con actividad de transferencia
CA3140358A1 (en) 2012-07-31 2014-02-06 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
AU2014243816B2 (en) 2013-03-13 2019-01-31 Bioasis Technologies Inc. Fragments of p97 and uses thereof
AU2015210612B2 (en) 2014-02-03 2020-04-09 Bioasis Technologies Inc. P97 fusion proteins
DK3107562T3 (da) 2014-02-19 2019-12-16 Bioasis Technologies Inc P97-ids-fusionsproteiner
WO2015168521A2 (fr) * 2014-05-01 2015-11-05 Bioasis Technologies, Inc. Conjugués p97-polynucléotides
EP3307326B9 (fr) 2015-06-15 2021-02-24 Angiochem Inc. Procédés de traitement d'une carcinomatose leptoméningée

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2116979A (en) * 1982-02-25 1983-10-05 Ward Page Faulk Conjugates of proteins with anti- tumour agents
EP0457250A2 (fr) * 1990-05-14 1991-11-21 Bristol-Myers Squibb Company Composés de liaison bifonctionnels, conjugués et leur procédé de production
DE4122210A1 (de) * 1991-07-04 1993-01-14 Deutsches Krebsforsch Konjugate aus tumoraktiver verbindung und protein sowie verfahren zu deren herstellung und ihre verwendung
WO1994001463A1 (fr) * 1992-07-10 1994-01-20 University Of British Columbia UTILISATION DE p97 ET DES PROTEINES LIANT LE FER COMME AGENTS DIAGNOSTIQUES ET THERAPEUTIQUES
WO2001059459A2 (fr) * 2000-02-08 2001-08-16 University Of British Columbia Compositions et procedes de selection d'agents therapeutiques

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2116979A (en) * 1982-02-25 1983-10-05 Ward Page Faulk Conjugates of proteins with anti- tumour agents
EP0457250A2 (fr) * 1990-05-14 1991-11-21 Bristol-Myers Squibb Company Composés de liaison bifonctionnels, conjugués et leur procédé de production
DE4122210A1 (de) * 1991-07-04 1993-01-14 Deutsches Krebsforsch Konjugate aus tumoraktiver verbindung und protein sowie verfahren zu deren herstellung und ihre verwendung
WO1994001463A1 (fr) * 1992-07-10 1994-01-20 University Of British Columbia UTILISATION DE p97 ET DES PROTEINES LIANT LE FER COMME AGENTS DIAGNOSTIQUES ET THERAPEUTIQUES
WO2001059459A2 (fr) * 2000-02-08 2001-08-16 University Of British Columbia Compositions et procedes de selection d'agents therapeutiques

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BEYER U ET AL: "Synthesis and in vitro efficacy of transferrin conjugates of the anticancer drug chlorambucil", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 41, no. 15, 25 June 1998 (1998-06-25), pages 2701 - 2708, XP002170971, ISSN: 0022-2623 *
BEYER U ET AL: "SYNTHESIS OF TRANSFERRIN AND ALBUMIN CONJUGATES OF THE ANCICANCER DRUGS CHLORAMBUCIL, DOXURUBICIN AND DAUNORUBICIN", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, ELSEVIER, AMSTERDAM, NL, vol. 4, no. SUPPL, 1996, pages S111, XP002062901, ISSN: 0928-0987 *
BICAMUMPAKA C ET AL: "IN VITRO CYTOTOXICITY OF PACLITAXEL-TRANSFERRIN CONJUGATE ON H69 CELLS", ONCOLOGY REPORTS, NATIONAL HELLENIC RESEARCH FOUNDATION, ATHENS, GR, vol. 5, no. 5, November 1998 (1998-11-01), pages 1381 - 1383, XP001094446, ISSN: 1021-335X *
KRATZ F ET AL: "Synthesis of new maleimide derivatives of daunorubicin and biological activity of acid labile transferrin conjugates", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 7, no. 5, 4 March 1997 (1997-03-04), pages 617 - 622, XP004136076, ISSN: 0960-894X *
KRATZ F ET AL: "TRANSFERRIN CONJUGATES OF DOXORUBICIN: SYNTHESIS, CHARACTERIZATION,CELLULAR UPTAKE, AND IN VITRO EFFICACY", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION. WASHINGTON, US, vol. 87, no. 3, 1 March 1998 (1998-03-01), pages 338 - 346, XP000736343, ISSN: 0022-3549 *
ROSE T M ET AL: "PRIMARY STRUCTURE OF THE HUMAN MELANOMA-ASSOCIATED ANTIGEN P97 (MELANOTRANSFERRIN) DEDUCED FROM THE MRNA SEQUENCE", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 83, March 1986 (1986-03-01), pages 1261 - 1265, XP002934311, ISSN: 0027-8424 *
TANAKA T ET AL: "SYNTHESIS OF TRANSFERRIN-MITOMYCIN C CONJUGATE AS A RECEPTOR- MEDIATED DRUG TARGETING SYSTEM", BIOLOGICAL & PHARMACEUTICAL BULLETIN (OF JAPAN), PHARMACEUTICAL SOCIETY OF JAPAN, JP, vol. 19, no. 5, 1 May 1996 (1996-05-01), pages 774 - 777, XP000594655, ISSN: 0918-6158 *

Also Published As

Publication number Publication date
AU2001285020A1 (en) 2002-02-25
WO2002013873A2 (fr) 2002-02-21
WO2002013873A9 (fr) 2003-01-30

Similar Documents

Publication Publication Date Title
WO2002013873A3 (fr) Compositions de composes conjugues a p97 et leurs methodes d'utilisation
WO2001062300A3 (fr) Therapie par promedicaments actives par une caspase
WO2007062093A3 (fr) Polytherapie pour le traitement du cancer
WO2002013843A3 (fr) Agents chimiotherapeutiques conjugues avec p97, et leurs utilisations pour le traitement des tumeurs neurologiques
WO2002042462A3 (fr) Agents therapeutiques et methodes d'utilisation de ces agents therapeutiques pour traiter une maladie amyloidogenique
WO2005120461A3 (fr) Formulations liposomales renfermant de la dihydrosphingomyeline, et procedes d'utilisation correspondants
CA2426703A1 (fr) Agents therapeutiques et procede d'utilisation de ces derniers pour modules l'angiogenese
WO2004111192A3 (fr) Liberation ciblee sur des cellules exprimant la legumaine
IL153297A0 (en) Compounds and compositions for delivering active agents
AU7445901A (en) Pharmaceutical compositions comprising cannabidiol derivatives
WO2003106659A3 (fr) Molecules toxine-aptamere et procedes d'utilisation correspondants
WO2006043083A8 (fr) Formulation cytotoxique pour therapie combinee
WO2005058233A3 (fr) Methodes de traitement d'une pancreatite aigue
UA87877C2 (en) Pegylated liposomal doxorubicin in combination with ecteinescidin 743
MXPA03010761A (es) Combinaciones farmaceuticas.
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
GB2368525A (en) Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
EP1279406A4 (fr) Transporteurs et systeme de distribution de medicament les utilisant
WO2002015959A3 (fr) Composes et compositions permettant de distribuer des agents actifs
WO2001068125A3 (fr) Methodes et compositions de traitement et de prevention de la dyserection
MXPA05007717A (es) Liberacion controlada de agentes altamente solubles.
WO2000072823A8 (fr) Preparations pour l'application d'agents anti-inflammatoires
AU2003290015A1 (en) Mastitis treatment
WO2005041936A3 (fr) Methodes de traitement du cancer
WO2005002516A3 (fr) Conjugues peptides-medicaments integres dans des leucocytes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 1/9-9/9, DRAWINGS, REPLACED BY NEW PAGES 1/9-9/9; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC. EPO FORM 1205A DATED 18.06.03

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP